BioPharma Resources

BLA 761069 · Astrazeneca Uk LTD

Imfinzi

Durvalumab · Injection · Programmed Death Ligand-1 Blocker

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

May 1, 2017

Approved uses

18

Original approval plus efficacy supplements

Registered trials

832

107 Phase 3, 174 recruiting

FAERS reports

21,581

20,621 serious, 6,844 with death reported

AI brief across all sources

Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 31, 2026.

IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. ( 1.1 ) • as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.1 ) • in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. ( 1.1 ) • as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.2 ) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) • in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) • in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.4 ) • in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient...

Mechanism: Expression of programmed cell death ligand-1 (PD-L1) can be induced by inflammatory signals (e.g., IFN-gamma) and can be expressed on both tumor cells and tumor-associated immune cells in the tumor microenvironment. PD-L1 blocks T-cell function and activation through interaction with PD-1 and CD80 (B7.1). By binding to its receptors, PD-L1 reduces cytotoxic T-cell activity, proliferation, and cytokine production. Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80 (B7.1). Blockade of PD-L1/PD-1...

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 13, 2026 Supplement 59 · Efficacy · priority review LabelMedication Guide
  • May 28, 2026 Supplement 53 · Efficacy LetterLabelMedication Guide
  • Nov 25, 2025 Supplement 52 · Efficacy · priority review Breakthrough therapyOrphanLetterLabel
  • Mar 28, 2025 Supplement 50 · Efficacy · priority review LabelLetter
  • Feb 28, 2025 Supplement 51 · Efficacy LabelLetter
  • Dec 4, 2024 Supplement 49 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Aug 15, 2024 Supplement 43 · Efficacy LetterLabel
  • Jun 14, 2024 Supplement 45 · Efficacy OrphanLabelLetter
  • Nov 10, 2022 Supplement 33 · Efficacy LabelLetter
  • Oct 21, 2022 Supplement 36 · Efficacy · priority review OrphanLetterLabel
  • Sep 2, 2022 Supplement 35 · Efficacy · priority review OrphanLabelLetter
  • Feb 19, 2021 Supplement 29 · Efficacy · priority review LetterLabel
  • Nov 18, 2020 Supplement 23 · Efficacy · priority review LabelLetter
  • Nov 18, 2020 Supplement 24 · Efficacy · priority review LabelLetter
  • Mar 27, 2020 Supplement 18 · Efficacy · priority review LabelLetter
  • Jul 19, 2019 Supplement 13 · Efficacy LabelLetter
  • Feb 16, 2018 Supplement 2 · Efficacy · priority review Breakthrough therapyLabelLetter
  • May 1, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalLabelLetterReview
1 products under this application
  • IMFINZI · DURVALUMAB 50MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Durvalumab" as an intervention, any sponsor and status, largest first.

All 832 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death4,160
  • malignant neoplasm progression1,703
  • pneumonitis900
  • radiation pneumonitis812
  • diarrhoea700
  • pyrexia670
  • off label use616
  • pneumonia500
  • dyspnoea495
  • interstitial lung disease491
  • fatigue484
  • asthenia478

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20168
2017168
2018769
20191,362
20201,456
20211,718
20221,511
20232,836
20243,709
20254,001
20264,043

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Imfinzi (Durvalumab)

2024 spending

$26.3M

Beneficiaries

463

2,290 claims

Per beneficiary

$56,803

$407.60 per unit

View as table
YearSpending
2020$8,125,802
2021$8,420,171
2022$12,360,160
2023$24,820,994
2024$26,299,907

Part B: Imfinzi (Durvalumab) · HCPCS J9173

2024 spending

$843M

Beneficiaries

14,791

79,678 claims

Per beneficiary

$56,999

2024 ASP limit $81.23 per unit

View as table
YearSpending
2020$505,845,758
2021$453,544,572
2022$562,741,221
2023$738,581,821
2024$843,071,958

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 607 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.